This leaves little in the way of market incentives for manufacturers to develop vaccines, unless there are large numbers of people who are at risk in wealthy countries.
Tootajate meelest pole selliste vaktsiinide tootmine majanduslikult tulus enne, kui haigus ei ohusta jõukamate riikide elanikke.